NeuroPace, Inc. (NPCE) Financial Analysis & Valuation | Quarter Chart
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system ... more
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $486.86M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | Joel D. Becker |
| IPO Date | 2021-04-22 | CAGR | 18.04% |
| Employees | 220 | Website | www.neuropace.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
NPCE chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $589.77M | P/E | -25.05 | Forward P/E | -65 | PEG | — |
| P/S | 4.17 | P/B | 34.55 | P/CF | -36.52 | P/FCF | -35.33 |
| Sales | $98.84M | Sales 1Y | 11.59% | Sales 3Y | 79.94% | Sales 5Y | 108.65% |
| EPS | $-0.57 | EPS 1Y | -31.94% | EPS 3Y | -66.37% | EPS 5Y | -53.25% |
| Sales QoQ | 3.43% | EPS QoQ | -10% | Sales QoQ Avg | -0.02% | EPS QoQ Avg | 12.84% |
| Gross Margin | 79.63% | Operating Margin | -15.26% | Profit Margin | -19.34% | ROCE | -18.95% |
| ROA | -20% | ROE | -120% | Altman Z Score | -3.23 | Piotroski Score | 3 |
| Current Ratio | 4.94 | Quick Ratio | 3.91 | Cash Ratio | 0.72 | Op. CF Ratio | -0.22 |
| Debt/Equity | 5.88 | Debt/Assets | 0.72 | Lt Debt/Equity | 5.7 | Lt Debt/Cap. | 0.85 |
| Intrst Cov. | -2.39 | Inventory Turnover | 1.11 | Asset Turnover | 1.02 | Receivables Turnover | 6.62 |
| Enterprise Value | $589.77M | P/E Ratio | -25.05 |
| Forward P/E | -65 | PEG Ratio | — |
| P/S Ratio | 4.17 | P/B Ratio | 34.55 |
| P/CF Ratio | -36.52 | P/FCF Ratio | -35.33 |
| EPS | $-0.57 | EPS Growth 1Y | -31.94% |
| EPS Growth 3Y | -66.37% | EPS Growth 5Y | -53.25% |
| Revenue Growth 1Y | 11.59% | Gross Margin | 79.63% |
| Operating Margin | -15.26% | Profit Margin | -19.34% |
| ROE | -120% | ROA | -20% |
| ROCE | -18.95% | Current Ratio | 4.94 |
| Quick Ratio | 3.91 | Cash Ratio | 0.72 |
| Debt/Equity | 5.88 | Interest Coverage | -2.39 |
| Altman Z Score | -3.23 | Piotroski Score | 3 |
NeuroPace, Inc. (NPCE) valuation & financials
NeuroPace, Inc. (NPCE) has a market capitalization of $486.86M and trades at a price-to-earnings ratio of -25.1. It operates in the Healthcare sector (Medical - Devices).
NeuroPace, Inc.'s revenue grew +11.6% over the last year.
NeuroPace, Inc.'s next earnings report is scheduled for November 3, 2026 after market close (provider scheduled date); analysts estimate EPS of $-0.09. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)